These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11164075)

  • 1. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches.
    Fant RV; Henningfield JE; Shiffman S; Strahs KR; Reitberg DP
    Pharmacol Biochem Behav; 2000 Nov; 67(3):479-82. PubMed ID: 11164075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers.
    DeVeaugh-Geiss AM; Chen LH; Kotler ML; Ramsay LR; Durcan MJ
    Clin Ther; 2010 Jun; 32(6):1140-8. PubMed ID: 20637967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise.
    Homsy W; Yan K; Houle JM; Besner JG; Gossard D; Pierce CH; Caillé G
    J Clin Pharmacol; 1997 Aug; 37(8):728-36. PubMed ID: 9378845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of smoking on the pharmacokinetics and pharmacodynamics of a nicotine patch.
    Yun HY; Seo JW; Choi JE; Baek IH; Kang W; Kwon KI
    Biopharm Drug Dispos; 2008 Dec; 29(9):521-8. PubMed ID: 19054833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic model of transdermal nicotine delivered from a matrix-type patch.
    Linakis MW; Rower JE; Roberts JK; Miller EI; Wilkins DG; Sherwin CMT
    Br J Clin Pharmacol; 2017 Dec; 83(12):2709-2717. PubMed ID: 28771779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine-mecamylamine interactions.
    Zevin S; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 2000 Jul; 68(1):58-66. PubMed ID: 10945316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking.
    Benowitz NL; Zevin S; Jacob P
    Br J Clin Pharmacol; 1997 Mar; 43(3):259-67. PubMed ID: 9088580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Mild Hyperthermia on Transdermal Absorption of Nicotine from Patches.
    Panda A; Sharma PK; Narasimha Murthy S
    AAPS PharmSciTech; 2019 Jan; 20(2):77. PubMed ID: 30635802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of nicotine pharmacokinetics in healthy Japanese male smokers following application of the transdermal nicotine patch and cigarette smoking.
    Sobue S; Sekiguchi K; Kikkawa H; Akasaki M; Irie S
    Biol Pharm Bull; 2006 May; 29(5):1068-73. PubMed ID: 16651750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nicotine administered via a transdermal delivery system on vigilance: a repeated measure study.
    Mancuso G; Andres P; Ansseau M; Tirelli E
    Psychopharmacology (Berl); 1999 Feb; 142(1):18-23. PubMed ID: 10102778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine.
    Vanakoski J; Seppälä T; Sievi E; Lunell E
    Clin Pharmacol Ther; 1996 Sep; 60(3):308-15. PubMed ID: 8841153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of a 24-hour nicotine patch and a 16-hour nicotine patch on smoking urges and sleep.
    Aubin HJ; Luthringer R; Demazières A; Dupont C; Lagrue G
    Nicotine Tob Res; 2006 Apr; 8(2):193-201. PubMed ID: 16766412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking.
    Rose JE; Behm FM; Westman EC
    Pharmacol Biochem Behav; 2001 Feb; 68(2):187-97. PubMed ID: 11267622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotine administration in rabbits using Habitrol nicotine patches and nicotine nasal spray.
    Sipe RV; Buck DC; Hollinger JO
    Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):480-2. PubMed ID: 10874502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a novel prolonged-release nicotine transdermal patch.
    Davaran S; Rashidi MR; Khandaghi R; Hashemi M
    Pharmacol Res; 2005 Mar; 51(3):233-7. PubMed ID: 15661573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17beta-estradiol matrixpatch removal and reapplication in postmenopausal women: theoretical predictions with an oscillating diffusion coefficient model.
    Rohr UD; Saeger-Lorenz K
    J Pharm Sci; 2002 Mar; 91(3):822-44. PubMed ID: 11920768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacokinetics of two nicotine transdermal systems: nicoderm and habitrol.
    Gupta SK; Okerholm RA; Eller M; Wei G; Rolf CN; Gorsline J
    J Clin Pharmacol; 1995 May; 35(5):493-8. PubMed ID: 7657849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial.
    Schuurmans MM; Diacon AH; van Biljon X; Bolliger CT
    Addiction; 2004 May; 99(5):634-40. PubMed ID: 15078238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation.
    Gschwend MH; Martin W; Arnold P; Verdun MO; Cambon N; Frentzel A; Scheiwe W
    Arzneimittelforschung; 2005; 55(7):403-13. PubMed ID: 16080280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotine delivery to users from cigarettes and from different types of e-cigarettes.
    Hajek P; Przulj D; Phillips A; Anderson R; McRobbie H
    Psychopharmacology (Berl); 2017 Mar; 234(5):773-779. PubMed ID: 28070620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.